Physician profile
Lia B Labrant
NPI 1053653105
$5,278.61
in general payments reported to CMS, 2019-2025
37 companies · $992 in 2025
The $992 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $366 · 2021: $1,078 · 2022: $808 · 2023: $790 · 2024: $830 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,362.72 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,162.16 | 2019-2025 | Injectafer |
| Coopersurgical, INC. | $309.40 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $273.07 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $199.18 | 2022-2025 | Thinprep 2000 Processor, Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Allergan, INC. | $194.73 | 2019-2020 | |
| Myovant Sciences INC. | $157.36 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $153.32 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.75 | 2019-2024 | |
| Evofem Biosciences, INC. | $142.90 | 2021-2025 | Solosec, Phexx, Phexxi |
| Therapeuticsmd, INC. | $139.87 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $139.77 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $134.96 | 2024-2025 | Veozah |
| Sage Therapeutics, LLC | $96.96 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $84.90 | 2019-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $82.93 | 2021-2024 | Twirla |
| Amag Pharmaceuticals, INC. | $64.41 | 2019 | |
| Millicent US INC | $61.27 | 2025 | Intrarosa, Femlyv |
| Baxter Healthcare | $48.95 | 2021 | |
| Merck Sharp & Dohme LLC | $26.98 | 2025 | Gardasil 9 |
| Shield Therapeutics INC | $24.93 | 2022 | |
| Scynexis, INC. | $23.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.05 | 2021 | |
| Exact Sciences Corporation | $19.03 | 2023 | Cologuard Collection Kit |
| Medicem INC. | $19.03 | 2021 | |
| Aspira Women'S Health INC | $18.64 | 2023 | Ova1 |
| Becton, Dickinson and Company | $18.40 | 2023 | Bd Onclarity |
| Duchesnay USA Incorporated | $17.47 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.11 | 2019 | |
| Lilly USA, LLC | $16.29 | 2025 | Mounjaro, Zepbound |
| Meditrina | $15.72 | 2024 | |
| Minerva Surgical, INC | $15.65 | 2024 | |
| Mission Pharmacal Company | $14.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.34 | 2023 | |
| Lupin INC. | $13.75 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $12.97 | 2023 | Vivjoa |
| Channel Medsystems, INC. | $8.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lia Labrant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.